DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20161498

Pharmacological role of atorvastatin in myocardium and smooth muscle progenitor cells

Suresh Kanna, Jai Prabu, Vignesh Marimuthu, Vijaya Anand

Abstract


Atorvastatin is a synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor with a great potency in the reduction of lipids and it has been well documented in both primary and secondary prevention studies. It exhibits pleiotropic properties in both in-vitro and in vivo conditions. Conversely, atorvastatin remain under-utilized in several situations. The main objective of this review is to focuses the pharmacological benefits, pleiotropic properties of the atorvastatin related to smooth muscle proliferation and myocardium.


Keywords


Atorvastatin, Smooth muscle cells, Angiotensin, Myocardium

Full Text:

PDF

References


Hadrava V, Kruppa U, Rrusso RC, Lacourciere Y, Tremblay J, Hamlet P. Vascular smooth muscle cell proliferation and its therapeutic modulation in hypertension. Am Heart J. 1991;122(4):1198-203.

Anand VA, Muneeb M, Divya N, Senthil R, Abdul Kapoor MM, Gowri J, et al. Clinical significance of hypertension, diabetes and inflammation, as predictor of cardiovascular disease. Int J Biol Med Res. 2011;2(1):369-73.

Anand VA, Chenniappan M, Kalavathy S, Uma K, Saravanan MP, Kumar SP. Redeeming measures of atorvastatin in the risk factors of cardiovascular diseases. International Journal of Pharmacology. 2008;4(4):305-9.

Metz RP, Patterson JL, Wilsn E. Vascular smooth muscle cells: isolation, culture, and characterization. Methods Mol Bio. 2012;843;169-76.

Keyes LE, Moore LG, Walchak SJ, Dempsey EC. Pregnancy stimulated growth of vascular smooth muscle cells: importance of protein kinase C-dependent synergy between estrogen and patelet-derived growth factor. J cell physiol. 1996;166(1);22-32.

Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation. 1998;98:82-9.

Wamhoff BR, Dixon JL, Sturek M. Atorvastatin treatment prevents alterations in coronary smoothmuscle nuclear Ca2+ signaling in diabetic dyslipidemia. J Vasc Res. 2002;39(3):208-20.

Xu CB, Stenman E, Edvinsson L. Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin. BiochemPharmacol. 2002;64(3):497-505.

Bruemmer D, Yin F, Liu J, Kiyono T, Fleck E, Van Herle A, Graf K, Law RE. Atorvastatin inhibits expression of minichromosome maintenance proteins in vascular smoothmuscle cells. Eur J Pharmacol. 2003;462(1-3):15-23.

Chandrasekar B, Mummidi S, Mahimainathan L, Patel DN, Bailey SR, Imam SZ, et al. Interleukin-18-induced human coronary artery smoothmuscle cell migration is dependent on NF-kappaB and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem. 2006;281(22):15099-109.

Kaneda T, Tsuruoka S, Fujimura A. Statins inhibited erythropoietin-induced proliferation of rat vascular smoothmuscle cells. Eur J Pharmacol. 2010;649(1-3):38-43.

Ali OF, Growcott EJ, Butrous GS, Wharton J. Pleiotropic effects of statins in distal human pulmonary artery smoothmuscle cells. Respir Res. 2011;12:137.

Li J, Yan W, Wang J, Tan W, Zhou Y, Yang K. Roles of periostin in proliferation and migration of vascular smoothmuscle cells and the effect of atorvastatin on them. Zhong Nan Da XueXueBao Yi Xue Ban. 2012;37(7):689-94.

Shyu KG, Chen SC, Wang BW, Cheng WP, Hung HF. Mechanism of the inhibitory effect of atorvastatin on leptin expression induced by angiotensin II in cultured human coronary artery smoothmuscle cells. Clin Sci (Lond). 2012;122(1):33-42.

Suski M, Gebska A, Olszanecki R, Stachowicz A, Uracz D, Madej J, et al. Influence of atorvastatin on angiotensin I metabolism in resting and TNF-α-activated rat vascular smooth muscle cells. J Renin Angiotensin Aldosterone Syst. 2013;15(4):378-83.

Thorburn J, Xu S, Thorburn A. MAP kinase-and Rho-dependent signals interact to regulate gene expression but not actin morphology in cardiac muscle cells. EMBO J. 1997;16:1888-900.

Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y. An HMGCo-A reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 2001;103:276-83.

Bendall JK, Cave AC, Heymes C, Gall N, Shah AM. Pivotal role of a gp91 (phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation. 2002;105:293-6.

Li JM, Gall NP, Grieve DJ, Chen M, Shah AM. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension. 2002;40:477-84.

Aikawa R, Komuro I, Yamazaki T, Zou Y, Kudoh S, Zhu W, et al. Rho family small G proteins play critical roles in mechanical stress-induced hypertrophic responses in cardiac myocytes. Circ Res. 1999;84:458-66.

Nakagami H, Jensen KS, Liao JK. A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med. 2003;35:398-403.

Xiao L, Pimentel DR, Wang J, Singh K, Colucci WS, Sawyer DB. Role of reactive oxygen species and NAD (P) H oxidase in alpha (1)-adrenoceptor signaling in adult rat cardiac myocytes. Am J Physiol Cell Physiol. 2002;282:C926-34.

Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, Kitakaze M, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108:1429-37.

Lee TM, Chou TF, Tsai CH. Association of pravastatin and left ventricular mass in hypercholesterolemic patients: role of 8-iso-prostaglandin f2alpha formation. J Cardiovasc Pharmacol. 2002;40:868-74.

Maack C, Kartes T, Kilter H, Schafers HJ, Nickenig G, Bohm M, Laufs U. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 2003;108:1567-74.

Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am CollCardiol. 2003;41(3):508-15.

Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997;3:249-54.

Drexler H. Endothelium as a therapeutic target in heart failure. Circulation. 1998;98:2652-5.

Laufs U, Kilter H, Konkol C, Wassmann S, Bohm M, Nickenig G. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res. 2002;53:911-20.

Chen HJ, Yao L, Chen TG, Yu M, Wang LH, Chen JZ. Atorvastatin prevents connexin43 remodeling in hypertrophied left ventricular myocardium of spontaneously hypertensive rats. Chin Med J (Engl). 2007;120(21):1902-7.